Profund Advisors LLC Purchases 31,997 Shares of Amicus Therapeutics, Inc. $FOLD

Profund Advisors LLC increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 57.5% during the second quarter, HoldingsChannel reports. The institutional investor owned 87,677 shares of the biopharmaceutical company’s stock after acquiring an additional 31,997 shares during the quarter. Profund Advisors LLC’s holdings in Amicus Therapeutics were worth $502,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in FOLD. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at about $3,760,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Amicus Therapeutics by 133.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,839,249 shares of the biopharmaceutical company’s stock worth $10,539,000 after purchasing an additional 1,053,015 shares during the last quarter. Bank of Montreal Can purchased a new stake in Amicus Therapeutics in the second quarter valued at approximately $144,000. Peregrine Capital Management LLC lifted its position in Amicus Therapeutics by 11.2% during the second quarter. Peregrine Capital Management LLC now owns 1,012,100 shares of the biopharmaceutical company’s stock valued at $5,799,000 after purchasing an additional 101,592 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its stake in Amicus Therapeutics by 7.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 64,607 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 4,303 shares in the last quarter.

Amicus Therapeutics Stock Up 1.1%

Shares of NASDAQ:FOLD opened at $9.42 on Thursday. The stock has a market capitalization of $2.91 billion, a P/E ratio of -78.49 and a beta of 0.66. The stock’s 50-day moving average price is $8.39 and its 200-day moving average price is $7.13. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $10.66.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The company had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. During the same period in the prior year, the business posted $0.10 EPS. Amicus Therapeutics’s quarterly revenue was up 19.5% compared to the same quarter last year. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on FOLD. Weiss Ratings restated a “sell (e+)” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 8th. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Thursday, September 18th. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.57.

Insider Activity at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the company’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93. Following the completion of the sale, the insider directly owned 322,618 shares in the company, valued at $3,068,097.18. This represents a 7.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.20% of the stock is currently owned by insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.